Cronos Group (NASDAQ:CRON) Stock Rating Upgraded by GMP Securities

Cronos Group (NASDAQ:CRON) was upgraded by investment analysts at GMP Securities from a “hold” rating to a “buy” rating in a report released on Friday, April 6th.

NASDAQ CRON traded down $0.35 during trading hours on Friday, reaching $7.02. 1,869,175 shares of the company were exchanged, compared to its average volume of 2,074,082. Cronos Group has a 1 year low of $1.00 and a 1 year high of $11.90. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.54 and a current ratio of 4.92.

ILLEGAL ACTIVITY WARNING: This article was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://stocknewstimes.com/2018/04/24/cronos-group-cron-raised-to-buy-at-gmp-securities.html.

About Cronos Group

Cronos Group Inc, formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada’s Marihuana for Medical Purposes Regulations (?MMPR?). The firm typically invests in companies based in Canada.

Receive News & Ratings for Cronos Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cronos Group and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply